The OBR Blog

April 24, 2017 - 11:04 pm Posted in AACR Conference Coverage comments0 Comments

Carlo Croce, MD, FAACR, is the recipient of the 2017 AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, presented to him at the 2017 AACR Annual Meeting. Dr. Croce, a leading researcher in cancer genetics, has won many awards over the duration of his career and is particularly proud to receive this one.

"What makes this award different from the others I have received is that is in the name of Margaret Foti, who is CEO of AACR. I have known Margaret for many years and watched her help shape the growth of AACR to become the organization that it is now. Margaret has always pushed for better cancer research. When I started my career, AACR was a small organization. Now the AACR Annual Meeting is the most important meeting for cancer research in the world. You will hear about the latest fundamental [basic], applied, and clinical research at this meeting.  Even the poster session is exciting," Dr. Croce told OBR.

Dr. Croce is director of the Institute of Genetics and director of the human cancer genetics program at The Ohio State University Comprehensive Cancer Center, and professor and chair of the Department of Molecular Virology, Immunology, and Medical Genetics at The Ohio State University School of Medicine in Columbus.

Margaret Foti, PhD, MD, said: "Dr. Croce is a highly esteemed basic and translational cancer researcher whose paradigm-shifting work has provided the basis for intensive investigations throughout the international scientific community. He has also provided extraordinary scientific leadership in the national and international scene, including research administration and mentorship of many talented young investigators, and he is greatly deserving of this award."

Among Dr. Croce's achievements is establishing the genetic links to a variety of cancers, including Burkitt lymphoma, T-cell lymphoma, and acute leukemia. His studies have shown that chromosomal abnormalities such as translations are capable of contributing to both cancer initiation and progression. He was the first investigator to discover and sequence BCL-2. More recently, his studies have focused on understanding the role of micro RNAs in cancer pathogenesis, including the potential for oncogenic or tumor suppressive properties.

When asked what he is particularly excited about right now, Dr. Croce said: "I am a cancer geneticist and I am excited about the whole field. Some people think cancer genetics is dead, but this is far from true. The more we understand about cancer genetics, the more we realize how complex this whole field is. For example, if we could better understand cancer initiation, we could find novel ways to treat cancer."

"We have a lot to learn. Only after we discover what all the changes in cancer genomics mean will we learn to treat cancer well. At first, we thought sequencing the genome would be the end-all, but this is the beginning. We have made much progress, but we need to continue to support more basic research to move forward and have better cancer treatments."

Dr. Croce is a lucky man for many reasons, not the least of which is his enduring passion for his work.
"I go to work with pleasure every day," he told OBR.

By John McCleery

April 18, 2017 - 05:04 pm Posted in AACR Conference Coverage comments0 Comments

Immunotherapy pioneer Carl June, MD, was named member of the 2017 class of fellows of the American Association for Cancer Research (AACR) Academy in April 2017, in recognition for his pivotal role in designing chimeric antigen receptor T cell immunotherapy (CAR-T) for the treatment of relapsed/refractory chronic lymphocytic leukemia.

Dr. June is director of the Center for Cellular Immunology in the Abramson Cancer Center and director of the Parker Institute for Cancer Immunotherapy at University of Pennsylvania School of Medicine.

When asked by OBR what this award means to him, Dr. June replied: “The AACR fellowship was a very special award for several reasons. First, the previous inductees are in many cases my most revered colleagues and mentors, who are literally the 'Who’s who' of cancer research. Secondly, the induction ceremony led by AACR leadership was very special.”

Dr. June began his research on genetically modified T cells in the 1990s when he was studying HIV/AIDS. This work led to his studying this technology in leukemia and the first clinical trials in leukemia patients in 2010. At that time, only three cancer centers had open CAR-T trials; now more than 110 CAR-T trials are open in the U.S. and other countries.

CAR-T cell therapy is still a work in progress. Although this therapy has achieved dramatic results in some patients with no other treatment options, it can also unleash the immune system to go awry, so much attention has focused on optimizing outcomes while taming unwanted immune responses.

The first pediatric patient to receive CAR-T therapy was Emily Whitehead, a 7-year-old child with intractable, seemingly fatal acute lymphoblastic leukemia. Her miraculous recovery made front-page headlines and she is alive and in remission at age 10.

Since then, scores of other patients with leukemias and other hematologic cancers have received CAR-T, with excellent and unprecedented remissions in many patients. The therapy is furthest along in development for the treatment of acute lymphocytic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma, and approval by the FDA is expected sometime in 2017.

CAR-T is also investigational in multiple myeloma and acute myeloid leukemia and in some sold tumors.

Dr. June continues his research on CAR-T and how best to exploit this novel approach. “The fundamental goal of CAR-T research is to contribute to the ultimate solution for cancer: curing and preventing,” he told OBR.

By John McCleery

article register

Recent Posts

Recent Comments

Archives

Categories